Stockscreener 앱 받기
2.21
3.91%
-0.09
전일 마감가:
$2.30
열려 있는:
$2.3
하루 거래량:
46,169
Relative Volume:
0.46
시가총액:
$164.06M
수익:
-
순이익/손실:
$-4.67M
주가수익비율:
-34.80
EPS:
-0.0635
순현금흐름:
-
1주 성능:
-0.45%
1개월 성능:
+28.49%
6개월 성능:
-41.99%
1년 성능:
+0.00%
1일 변동 폭
$2.1302
$2.30
1주일 범위
$2.07
$2.30
52주 변동 폭
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.21 | 164.06M | 0 | -4.67M | 0 | -0.0635 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jyong Biotech Ltd 주식(MENS)의 최신 뉴스
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business
Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria
Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang
Jyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026 - Stock Titan
Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey
Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
MENSJyong Biotech Ltd Stock Price and Quote - Finviz
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com
Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative
DXS INTERNATIONAL PLC (AQSE: DXSP): Issue of New Shares and Notification of Director / PDMR Dealings - Weekly Voice
Jyong Biotech Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
What Jyong Biotech (MENS) management focus reveals about priorities (Risk Aversion) 2026-05-11Crowd Sentiment Stocks - Newser
Jyong Biotech Delays Annual 20-F (Yearly Report) - The Globe and Mail
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - The Manila Times
Jyong Biotech Updates Market Access Strategy for Innovative - GlobeNewswire
Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2% - MarketBeat
CEO-linked entities report 33.34% Jyong Biotech (MENS) stake via trust - Stock Titan
Jyong Biotech (MENS) Management Strategy | Q1 2025: Earnings ReportPre Earnings - Cổng thông tin điện tử tỉnh Lào Cai
Who Backs Jyong Biotech (MENS) Stock (Risk Aversion) 2026-04-20Investment Picks - Cổng thông tin điện tử tỉnh Lào Cai
Ming Tsan Hsu Net Worth (2026) - GuruFocus
Pang Chieh Chi Net Worth (2026) - GuruFocus
Hung Shu Fan Net Worth (2026) - GuruFocus
Feng Lin Hsu Net Worth (2026) - GuruFocus
Jyong Biotech Ltd (MENS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):